ArticleEJNMMI research2026
Dosimetry of [
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn this case study, we share our experience on the treatment of a patient with [177Lu]Lu-PSMA for metastatic castration-resistant prostate cancer and comorbid kidney failure. Since a poor kidney function impacts [177Lu]Lu-PSMA clearance, the aim of this study was to carefully monitor the radiation dose to the organs-at-risk, and measure the activity distribution during hemodialysis sessions, by imaging, blood sampling and dialysate sampling. CASE PRESENTATION: A 72-year-old patient received a total of five cycles of approximately 7.4 GBq [177Lu]Lu-PSMA-I&T, with an interval of 5–7 weeks per cycle. The radiation dose per cycle (mean ± SD) was measured for different regions: total body 0.51 ± 0.06 Gy, liver (incl. tumours) 5.6 ± 0.5 Gy, kidney (single, poor function) 3.3 ± 0.4 Gy, salivary glands 5.5 ± 0.7 Gy, and bone marrow 0.41 ± 0.07 Gy. Hemodialysis was continued three times a week. Precautions for radiation protection were taken for the first hemodialysis session 20 h after [177Lu]Lu-PSMA administration, which took place at the radioligand therapy nursery unit. Blood and dialysate samples, collected during hemodialysis, showed a drop of the activity concentration in the blood of the patient (32% in 3 h), and a partial return of activity to the blood (rebound effect) after the end of the hemodialysis treatment. The radiation dose to the bone marrow of the hemodialysis patient was elevated (by a factor of two as compared to literature), but stayed below dose thresholds for severe deterministic side effects.
conclusionsDespite the preexisting kidney failure of a hemodialysis patient, the carefully monitored radiation dose of [177Lu]Lu-PSMA therapy remained below safe dose thresholds and no signs of severe hematotoxicity were observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.